BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $4568.T readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04433234-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:DS-5141b readout (P2) · Daiichi Sankyo Co.\, Ltd. $4568.T
DESCRIPTION:Long-term\, Extension Study of DS-5141b in Patients With Duchen
 ne Muscular Dystrophy\n\nPrimary completion date: 2027-01-31 (estimated)\n
 Originally planned: 2022-03-31 (+58.0 months)\nPhase 2 · Rare · Duchenne
  Muscular Dystrophy\nEnrollment: 8 · Sites: 2\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04433
 234\nhttps://clinicaltrials.gov/study/NCT04433234
URL:https://datacutoff.com/radar.html?nct=NCT04433234
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan readout (P3) · Daiichi Sankyo $4568.T
DESCRIPTION:Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Rec
 eptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metast
 atic Breast Cancer\n\nPrimary completion date: 2027-10-01 (estimated)\nPha
 se 3 · Oncology · Breast Cancer\nEnrollment: 250 · Sites: 88\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT05950945\nhttps://clinicaltrials.gov/study/NCT05950945
URL:https://datacutoff.com/radar.html?nct=NCT05950945
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
